CJPR

Previous Articles     Next Articles

  

  • Online:2017-07-01 Published:2017-06-30

从液体活检谈进展期胰腺癌的合理治疗

楼文晖a刘霄宇b   

  1. 复旦大学附属中山医院  a.普外科  b.介入科,上海200032

Abstract:

Individualized treatment  of advanced pancreatic carcinoma with special reference to liquid biopsy        LOU Wen-hui*,LIU Xiao-yu. *Department of General Surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China
Corresponding author:LOU Wen-hui,E-mail:lou.wenhui@
zs-hospital.sh.cn
Abstract    The advantage of liquid biopsy in pancreatic cancer lies in minimal invasive, repeatable, and coherent to pathological diagnosis. Circulating tumor cells (CTCs) and Circulating cell-free DNA (cfDNA) are the major parts of liquid biopsy, there will be good perspertive in the personalized therapy of pancreatic cancer. Standardized technique, reasonable interpretation of the result will be the fundation of liquid biopsy in pancreatic cancer. Dynamically monitoring the change of CTC and cfDNA will provide clue for discovering new markers of recurrence and metastasis, as weill as new target of treatment.

Key words: advanced pancreatic carcinoma, liquid biopsy, circulating tumor cells, circulating cell-free DNA

摘要:

液体活检在进展期胰腺癌诊断、治疗中的优势在于创伤小,便于重复采样,在很大程度上接近病理学诊断的敏感度和特异度。循环肿瘤细胞(CTCs)和循环游离DNA(cfDNA)是液体活检的重要组成部分,在胰腺癌的个体化诊疗中具有重要临床应用前景。规范检测技术、合理解读检测结果,将是液体活检指导胰腺癌个体化治疗的基础;动态监测cfDNA和CTCs的变化,将为找寻胰腺癌复发、转移标记物以及胰腺癌治疗新靶点提供线索。

关键词: 进展期胰腺癌, 液体活检, 循环肿瘤细胞, 循环游离DNA